Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Puma Biotechnology, Inc. (PBYI) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Puma Biotechnology, Inc. (PBYI) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for January 6th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 6:
NRx Pharmaceuticals, Inc. (NRXP - Free Report) : This bio-pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 46.2% over the last 60 days.
NRx Pharmaceuticals, Inc. Price and Consensus
NRx Pharmaceuticals, Inc. price-consensus-chart | NRx Pharmaceuticals, Inc. Quote
NRx Pharmaceuticals' shares gained 79.3% over the last three months compared with the S&P 500’s advanced of 4.2%. The company possesses a Momentum Score of A.
NRx Pharmaceuticals, Inc. Price
NRx Pharmaceuticals, Inc. price | NRx Pharmaceuticals, Inc. Quote
Pro-Dex, Inc. (PDEX - Free Report) : This medical device contract manufacturer company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 40.9% over the last 60 days.
Pro-Dex, Inc. Price and Consensus
Pro-Dex, Inc. price-consensus-chart | Pro-Dex, Inc. Quote
Pro-Dex's shares gained 67.7% over the last three months compared with the S&P 500’s advanced of 4.2%. The company possesses a Momentum Score of A.
Pro-Dex, Inc. Price
Pro-Dex, Inc. price | Pro-Dex, Inc. Quote
Puma Biotechnology, Inc. (PBYI - Free Report) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 24% over the last 60 days.
Puma Biotechnology, Inc. Price and Consensus
Puma Biotechnology, Inc. price-consensus-chart | Puma Biotechnology, Inc. Quote
Puma Biotechnology's shares gained 10.9% over the last three months compared with the S&P 500’s advanced of 4.2%. The company possesses a Momentum Score of A.
Puma Biotechnology, Inc. Price
Puma Biotechnology, Inc. price | Puma Biotechnology, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.